Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Geron closes $97.3mm public offering

Executive Summary

Cancer therapeutics developer Geron Corp. netted $97.3mm through the public sale of 25.9mm common shares (including the overallotment) at $4. The company will use some of the proceeds to fund an upcoming Phase II trial of the telomerase inhibitor imetelstat for myelofibrosis.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register